Cargando…

Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis

(1) Background: Anti-carbamylated protein (CarP) antibodies have been studied as novel markers to aid in the diagnosis and prognosis of rheumatoid arthritis. (2) Methods: A total of 265 samples were included in the evaluation, for which 98 had results for anti-cyclic citrullinated peptide (CCP), 86...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricchiuti, Vincent, Chun, Kelly Y., Yang, Jane M., Aure, Mary Ann, Gomez, Luis, Norman, Gary L., Mahler, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318554/
https://www.ncbi.nlm.nih.gov/pubmed/35885566
http://dx.doi.org/10.3390/diagnostics12071661
_version_ 1784755321256804352
author Ricchiuti, Vincent
Chun, Kelly Y.
Yang, Jane M.
Aure, Mary Ann
Gomez, Luis
Norman, Gary L.
Mahler, Michael
author_facet Ricchiuti, Vincent
Chun, Kelly Y.
Yang, Jane M.
Aure, Mary Ann
Gomez, Luis
Norman, Gary L.
Mahler, Michael
author_sort Ricchiuti, Vincent
collection PubMed
description (1) Background: Anti-carbamylated protein (CarP) antibodies have been studied as novel markers to aid in the diagnosis and prognosis of rheumatoid arthritis. (2) Methods: A total of 265 samples were included in the evaluation, for which 98 had results for anti-cyclic citrullinated peptide (CCP), 86 for rheumatoid factor (RF), and 212 for 14-3-3 eta protein. Anti-CarP antibodies were measured using a fetal calf serum-based single-step assay (research use only, Inova Diagnostics, San Diego, CA). (3) Results: Anti-CarP antibodies were significantly higher and more frequent in anti-CCP3.1+ (p = 0.0025), RF+ (p = 0.0043) and 14-3-3 eta+ (p = 0.028) samples compared to the negative counterpart group. In addition, isolated anti-CarP positivity occurred in samples negative for anti-CCP3.1, RF, or 14-3-3 eta. When anti-CarP antibodies were compared to each of the RF, anti-CCP3.1, and 14-3-3 eta by receiver operating characteristic (ROC) analyses, the area under the curve (AUC) values of 0.71 (RF), 0.68 (anti-CCP3.1), and 0.59 (14-3-3 eta), respectively, demonstrated a moderate correlation. Using an UpSet plot, we determined that 10.6% of the samples with available results for anti-CCP3.1, RF, and anti-CarP showed triple positivity. (4) Conclusions: Anti-carbamylated protein (anti-CarP) antibodies can be detected in anti-CCP, RF and 14-3-3 eta-positive and -negative patients, potentially identifying specific subsets of patients.
format Online
Article
Text
id pubmed-9318554
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93185542022-07-27 Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis Ricchiuti, Vincent Chun, Kelly Y. Yang, Jane M. Aure, Mary Ann Gomez, Luis Norman, Gary L. Mahler, Michael Diagnostics (Basel) Brief Report (1) Background: Anti-carbamylated protein (CarP) antibodies have been studied as novel markers to aid in the diagnosis and prognosis of rheumatoid arthritis. (2) Methods: A total of 265 samples were included in the evaluation, for which 98 had results for anti-cyclic citrullinated peptide (CCP), 86 for rheumatoid factor (RF), and 212 for 14-3-3 eta protein. Anti-CarP antibodies were measured using a fetal calf serum-based single-step assay (research use only, Inova Diagnostics, San Diego, CA). (3) Results: Anti-CarP antibodies were significantly higher and more frequent in anti-CCP3.1+ (p = 0.0025), RF+ (p = 0.0043) and 14-3-3 eta+ (p = 0.028) samples compared to the negative counterpart group. In addition, isolated anti-CarP positivity occurred in samples negative for anti-CCP3.1, RF, or 14-3-3 eta. When anti-CarP antibodies were compared to each of the RF, anti-CCP3.1, and 14-3-3 eta by receiver operating characteristic (ROC) analyses, the area under the curve (AUC) values of 0.71 (RF), 0.68 (anti-CCP3.1), and 0.59 (14-3-3 eta), respectively, demonstrated a moderate correlation. Using an UpSet plot, we determined that 10.6% of the samples with available results for anti-CCP3.1, RF, and anti-CarP showed triple positivity. (4) Conclusions: Anti-carbamylated protein (anti-CarP) antibodies can be detected in anti-CCP, RF and 14-3-3 eta-positive and -negative patients, potentially identifying specific subsets of patients. MDPI 2022-07-08 /pmc/articles/PMC9318554/ /pubmed/35885566 http://dx.doi.org/10.3390/diagnostics12071661 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Ricchiuti, Vincent
Chun, Kelly Y.
Yang, Jane M.
Aure, Mary Ann
Gomez, Luis
Norman, Gary L.
Mahler, Michael
Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis
title Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis
title_full Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis
title_fullStr Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis
title_full_unstemmed Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis
title_short Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis
title_sort anti-carbamylated protein (anti-carp) antibodies in patients evaluated for suspected rheumatoid arthritis
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318554/
https://www.ncbi.nlm.nih.gov/pubmed/35885566
http://dx.doi.org/10.3390/diagnostics12071661
work_keys_str_mv AT ricchiutivincent anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis
AT chunkellyy anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis
AT yangjanem anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis
AT auremaryann anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis
AT gomezluis anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis
AT normangaryl anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis
AT mahlermichael anticarbamylatedproteinanticarpantibodiesinpatientsevaluatedforsuspectedrheumatoidarthritis